EGFR and glioblastoma: Evaluated treatments with bevacizumab [45], dendritic cell vaccination [46], EGFR-targeted immunotherapy [47], and integrin or mTOR inhibitors [48] have, to date, all failed to show any benefit for patients with glioblastoma, wherefore patients have remained on the same standard of therapy with surgery and radiochemotherapy with temozolomide.